6-[2-(3,3-Dimethylbutoxy)ethoxy]-2,2-dimethylhexan-3-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 6-[2-(3,3-Dimethylbutoxy)ethoxy]-2,2-dimethylhexan-3-one
• 英文别名: 6-[2-(3,3-dimethylbutoxy)ethoxy]-2,2-dimethylhexan-3-one
• 化学式: C₁₆H₃₂O₃
• 分子量: 272.42
• InChiKey: IEAAFJKJJMRZHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• IMMUNOMODULATORS AND IMMUNOMODULATOR CONJUGATES
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US20170217960A1

  公开（公告）日：2017-08-03

  The invention provides compounds of formula I: wherein R 1 —R 3 , R a , and R b have any of the values defined herein, and salts thereof. The compounds have immunomodulatory properties.

  该发明提供了公式I的化合物：其中R1至R3，Ra和Rb具有本文中定义的任何值，及其盐。这些化合物具有免疫调节特性。
• NOVEL CONJUGATES OF CC-1065 ANALOGS AND BIFUNCTIONAL LINKERS
  申请人：Beusker Patrick Henry

  公开号：US20130224227A1

  公开（公告）日：2013-08-29

  This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
• Novel Conjugates of CC-1065 Analogs and Bifunctional Linkers
  申请人：SYNTARGA BV

  公开号：US20170274090A1

  公开（公告）日：2017-09-28

  This invention relates to novel analogs of the DNA-alkylating agent CC-1065 and to their conjugates. Furthermore this invention concerns intermediates for the preparation of said agents and conjugates. The conjugates are designed to release their (multiple) payload after one or more activation steps and/or at a rate and time span controlled by the conjugate in order to selectively deliver and/or controllably release one or more of said DNA alkylating agents. The agents, conjugates, and intermediates can be used to treat an illness that is characterized by undesired (cell) proliferation. As an example, the agents and the conjugates of this invention may be used to treat a tumor.
• FUNCTIONALIZED NANOLUC INHIBITORS
  申请人：PROMEGA CORPORATION

  公开号：US20180222916A1

  公开（公告）日：2018-08-09

  Compounds that may inhibit Oplophorus -derived luciferases are disclosed as well as compositions and kits comprising the compounds, and methods of using the compounds.
• US9034336B2
  申请人：——

  公开号：US9034336B2

  公开（公告）日：2015-05-19